BTG narrows focus to pharmaceuticals & medical technologies
This article was originally published in Clinica
Executive Summary
Declining revenues and rising losses at UK technology developer BTG has led CEO Louise Makin to narrow the company's remit. It will no longer seek new opportunities in the physical sciences sector but will focus on pharmaceuticals and other medical technologies, said Ms Makin, who was appointed in October 2004.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.